Researchers for the MOSAIC2 trial, which was conducted over 3 years at the Centre for Eye Research Ireland, explored the safety and effectiveness of different atropine concentrations in controlling myopia progression in European children. The study group concluded that low-concentration atropine eye drops may have proportional treatment effects that are relative to untreated myopia progression. The clinical trial indicated that atropine treatment benefits may be greater for patients with higher myopia progression, especially in slower-progressing European populations. The researchers recommended further studies to assess long-term outcomes and treatment protocols for different demographic groups.

Source: JAMA Ophthalmology